230 related articles for article (PubMed ID: 20132813)
1. KR-003048, a potent, orally active inhibitor of p38 mitogen-activated protein kinase.
Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Ernst J; Gibbs A; Kahl J; Kessler L; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Wang Z; Larson CJ
Eur J Pharmacol; 2010 Apr; 632(1-3):93-102. PubMed ID: 20132813
[TBL] [Abstract][Full Text] [Related]
2. DBM1285 suppresses tumor necrosis factor alpha production by blocking p38 mitogen-activated protein kinase/mitogen-activated protein kinase-activated protein kinase 2 signaling pathway.
Kang JS; Kim HM; Choi IY; Han SB; Yoon YD; Lee H; Park KH; Cho IJ; Lee CW; Lee K; Lee KH; Park SK
J Pharmacol Exp Ther; 2010 Aug; 334(2):657-64. PubMed ID: 20427474
[TBL] [Abstract][Full Text] [Related]
3. Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation.
Hope HR; Anderson GD; Burnette BL; Compton RP; Devraj RV; Hirsch JL; Keith RH; Li X; Mbalaviele G; Messing DM; Saabye MJ; Schindler JF; Selness SR; Stillwell LI; Webb EG; Zhang J; Monahan JB
J Pharmacol Exp Ther; 2009 Dec; 331(3):882-95. PubMed ID: 19720877
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological profile of AW-814141, a novel, potent, selective and orally active inhibitor of p38 MAP kinase.
Chopra P; Kulkarni O; Gupta S; Bajpai M; Kanoje V; Banerjee M; Bansal V; Visaga S; Chatterjee M; Chaira T; Shirumalla RK; Verma AK; Dastidar SG; Sharma G; Ray A
Int Immunopharmacol; 2010 Apr; 10(4):467-73. PubMed ID: 20093202
[TBL] [Abstract][Full Text] [Related]
5. Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity.
Hill RJ; Dabbagh K; Phippard D; Li C; Suttmann RT; Welch M; Papp E; Song KW; Chang KC; Leaffer D; Kim YN; Roberts RT; Zabka TS; Aud D; Dal Porto J; Manning AM; Peng SL; Goldstein DM; Wong BR
J Pharmacol Exp Ther; 2008 Dec; 327(3):610-9. PubMed ID: 18776065
[TBL] [Abstract][Full Text] [Related]
6. SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence.
Underwood DC; Osborn RR; Kotzer CJ; Adams JL; Lee JC; Webb EF; Carpenter DC; Bochnowicz S; Thomas HC; Hay DW; Griswold DE
J Pharmacol Exp Ther; 2000 Apr; 293(1):281-8. PubMed ID: 10734180
[TBL] [Abstract][Full Text] [Related]
7. 5-Cyanopyrimidine derivatives as a novel class of potent, selective, and orally active inhibitors of p38alpha MAP kinase.
Liu C; Wrobleski ST; Lin J; Ahmed G; Metzger A; Wityak J; Gillooly KM; Shuster DJ; McIntyre KW; Pitt S; Shen DR; Zhang RF; Zhang H; Doweyko AM; Diller D; Henderson I; Barrish JC; Dodd JH; Schieven GL; Leftheris K
J Med Chem; 2005 Oct; 48(20):6261-70. PubMed ID: 16190753
[TBL] [Abstract][Full Text] [Related]
8. T cell activation signals up-regulate p38 mitogen-activated protein kinase activity and induce TNF-alpha production in a manner distinct from LPS activation of monocytes.
Schafer PH; Wang L; Wadsworth SA; Davis JE; Siekierka JJ
J Immunol; 1999 Jan; 162(2):659-68. PubMed ID: 9916683
[TBL] [Abstract][Full Text] [Related]
9. Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of nuclear factor-kappaB, p38 mitogen-activated protein kinase, and c-Jun NH2-terminal kinase activation.
Kwak HJ; Song JS; Heo JY; Yang SD; Nam JY; Cheon HG
J Pharmacol Exp Ther; 2005 Dec; 315(3):1188-95. PubMed ID: 16126838
[TBL] [Abstract][Full Text] [Related]
10. Discovery and characterization of triaminotriazine aniline amides as highly selective p38 kinase inhibitors.
Lin TH; Metzger A; Diller DJ; Desai M; Henderson I; Ahmed G; Kimble EF; Quadros E; Webb ML
J Pharmacol Exp Ther; 2006 Aug; 318(2):495-502. PubMed ID: 16702443
[TBL] [Abstract][Full Text] [Related]
11. Novel inhibitor of p38 MAP kinase as an anti-TNF-alpha drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent.
Miwatashi S; Arikawa Y; Kotani E; Miyamoto M; Naruo K; Kimura H; Tanaka T; Asahi S; Ohkawa S
J Med Chem; 2005 Sep; 48(19):5966-79. PubMed ID: 16162000
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-18 enhances monocyte tumor necrosis factor alpha and interleukin-1beta production induced by direct contact with T lymphocytes: implications in rheumatoid arthritis.
Dai SM; Matsuno H; Nakamura H; Nishioka K; Yudoh K
Arthritis Rheum; 2004 Feb; 50(2):432-43. PubMed ID: 14872485
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitors.
Hynes J; Dyckman AJ; Lin S; Wrobleski ST; Wu H; Gillooly KM; Kanner SB; Lonial H; Loo D; McIntyre KW; Pitt S; Shen DR; Shuster DJ; Yang X; Zhang R; Behnia K; Zhang H; Marathe PH; Doweyko AM; Tokarski JS; Sack JS; Pokross M; Kiefer SE; Newitt JA; Barrish JC; Dodd J; Schieven GL; Leftheris K
J Med Chem; 2008 Jan; 51(1):4-16. PubMed ID: 18072718
[TBL] [Abstract][Full Text] [Related]
14. Regulation of monocyte IL-10 synthesis by endogenous IL-1 and TNF-alpha: role of the p38 and p42/44 mitogen-activated protein kinases.
Foey AD; Parry SL; Williams LM; Feldmann M; Foxwell BM; Brennan FM
J Immunol; 1998 Jan; 160(2):920-8. PubMed ID: 9551930
[TBL] [Abstract][Full Text] [Related]
15. Suppression of lipopolysaccharide-induced cytokine production of gingival fibroblasts by a soybean, Kunitz trypsin inhibitor.
Kobayashi H; Yoshida R; Kanada Y; Fukuda Y; Yagyu T; Inagaki K; Kondo T; Kurita N; Suzuki M; Kanayama N; Terao T
J Periodontal Res; 2005 Dec; 40(6):461-8. PubMed ID: 16302924
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of p38 mitogen-activated protein kinase prevents inflammatory bone destruction.
Mbalaviele G; Anderson G; Jones A; De Ciechi P; Settle S; Mnich S; Thiede M; Abu-Amer Y; Portanova J; Monahan J
J Pharmacol Exp Ther; 2006 Jun; 317(3):1044-53. PubMed ID: 16501068
[TBL] [Abstract][Full Text] [Related]
17. RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase.
Wadsworth SA; Cavender DE; Beers SA; Lalan P; Schafer PH; Malloy EA; Wu W; Fahmy B; Olini GC; Davis JE; Pellegrino-Gensey JL; Wachter MP; Siekierka JJ
J Pharmacol Exp Ther; 1999 Nov; 291(2):680-7. PubMed ID: 10525088
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase.
Liverton NJ; Butcher JW; Claiborne CF; Claremon DA; Libby BE; Nguyen KT; Pitzenberger SM; Selnick HG; Smith GR; Tebben A; Vacca JP; Varga SL; Agarwal L; Dancheck K; Forsyth AJ; Fletcher DS; Frantz B; Hanlon WA; Harper CF; Hofsess SJ; Kostura M; Lin J; Luell S; O'Neill EA; O'Keefe SJ
J Med Chem; 1999 Jun; 42(12):2180-90. PubMed ID: 10377223
[TBL] [Abstract][Full Text] [Related]
19. Mitogen-activated protein kinase phosphatase-1 negatively regulates the expression of interleukin-6, interleukin-8, and cyclooxygenase-2 in A549 human lung epithelial cells.
Turpeinen T; Nieminen R; Moilanen E; Korhonen R
J Pharmacol Exp Ther; 2010 Apr; 333(1):310-8. PubMed ID: 20089808
[TBL] [Abstract][Full Text] [Related]
20. In vivo and in vitro cytokine modulatory activity of newly synthesised 2-aminotetraline derivatives.
Ruggiero V; Piovesan P; Fabrizi C; Lauro GM; Campo S; Albertoni C; Nucera E; Carminati P; Ghirardi O
Shock; 2004 Jan; 21(1):77-85. PubMed ID: 14676688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
